Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
99 hedge funds and large institutions have $585M invested in Albireo Pharma Inc in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 43 reducing their positions, and 9 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
1% less capital invested
Capital invested by funds: $589M → $585M (-$4.25M)
6% less call options, than puts
Call options by funds: $3.29M | Put options by funds: $3.5M
1% less funds holding
Funds holding: 100 → 99 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
33% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$4.64M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$4.06M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.32M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.04M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$693K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$17.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$7.16M |
| 3 |
State Street
Boston,
Massachusetts
|
-$5.08M |
| 4 |
Two Sigma Investments
New York
|
-$4.79M |
| 5 |
Goldman Sachs
New York
|
-$2.99M |
ALBO Hedge Fund Activity: Q2 2021 in Review
99 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2021, worth a combined $585M — down 0.72% from $589M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALBO and 8 opened new positions — a net loss of 1 holder — while 43 trimmed existing stakes and 29 added.
The largest buyer was Platinum Investment Management, adding an estimated $4.64M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $17.6M sold.
- 99 institutional investors held Albireo Pharma Inc (ALBO) as of Q2 2021, down from 100 in Q1 2021.
- Funds reported $585M of Albireo Pharma Inc stock for Q2 2021, down 0.72% quarter-over-quarter.
- 8 funds opened new Albireo Pharma Inc positions in Q2 2021 and 9 closed out, a net change of -1 holder.
- The largest Albireo Pharma Inc buyer in Q2 2021 was Platinum Investment Management, an estimated $4.64M added.
- The largest Albireo Pharma Inc seller in Q2 2021 was Cormorant Asset Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q2 2021.